Background
Erythropoietin analogues and intravenous iron supplementation are used to treat anemia in hemodialysis patients. Treatment guidelines suggest a target range for hemoglobin levels in hemodialysis patients of 6.8 to 7.4 mmol/l. Before start of the study, 23% of all hemodialysis patients in our hospital had hemoglobin levels within target range. In this study, we investigated if pharmacy-based dosing of darbepoetin was more effective in reaching target hemoglobin (Hb) levels than physician-based dosing.
Methods

•
Single-center randomized, controlled trial -n=2x100
• Inclusion criteria Darbepoetin dosage per patient in the intervention group was 13 mcg/week lower than in the control group.
Discussion
The increase in percentage of hemoglobin levels within target range was not as high as expected, probably due to the high frequency of infections.
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